The Use of “Added Benefit” To Determine the Price of New Anti-Cancer Drugs In France, 2004-2017, by Marc Rodwin
Marc Rodwin, holder of the Chair in Integrated Cancer Research, joined with the IPC from september 2017 to july 2018, has writen an article published in the European Journal of Cancer.